Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

Michael E. Weinblatt, Joan M. Bathon, Joel M. Kremer, Roy M. Fleischmann, Michael H. Schiff, Richard W. Martin, Scott W. Baumgartner, Grace S. Park, Edward L. Mancini, Mark C. Genovese

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the long-term safety and efficacy of etanercept therapy in rheumatoid arthritis (RA) patients. Methods. Adult patients with early RA or longstanding RA received etanercept in open-label extension studies following initial double-blind trials of etanercept. Results. Of 558 early RA patients and 714 longstanding RA patients who received at least 1 dose of etanercept, a total of 194 early RA patients and 217 longstanding RA patients were treated with 25 mg of etanercept twice weekly through 10 years. Five opportunistic infections were reported: in early RA, 1 Candida septicemia; in longstanding RA, 1 herpes zoster, 1 atypical mycobacterium infection, 1 meningoencephalitis (unspecified), and 1 fungal sepsis (unspecified). Twenty-nine cases of sepsis occurred (10 early RA, 19 longstanding RA). Occurrence of all malignancies was similar to that expected in the general population, but the occurrence of lymphomas was higher than expected in the general population. Fourteen lymphomas (7 early RA, 7 longstanding RA) and 2 cases of demyelinating disease (1 early RA, 1 longstanding RA) were reported. Deaths occurred in 18 early RA patients and 43 longstanding RA patients. Both patient groups showed sustained improvement in American College of Rheumatology responses, swollen joint counts, Health Assessment Questionnaire disability index scores, and C-reactive protein levels. Conclusion. Etanercept maintained therapeutic benefits beyond 10 years of therapy in both early RA and longstanding RA patients, suggesting that etanercept is well tolerated and effective as a long-term, continuous therapy for the treatment of RA, with a favorable risk/benefit ratio.

Original languageEnglish (US)
Pages (from-to)373-382
Number of pages10
JournalArthritis Care and Research
Volume63
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Safety
Therapeutics
Etanercept
Sepsis
Lymphoma
Nontuberculous Mycobacterium Infections
Meningoencephalitis
Opportunistic Infections
Herpes Zoster
Demyelinating Diseases
Candida
C-Reactive Protein
Population

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Weinblatt, M. E., Bathon, J. M., Kremer, J. M., Fleischmann, R. M., Schiff, M. H., Martin, R. W., ... Genovese, M. C. (2011). Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care and Research, 63(3), 373-382. https://doi.org/10.1002/acr.20372

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. / Weinblatt, Michael E.; Bathon, Joan M.; Kremer, Joel M.; Fleischmann, Roy M.; Schiff, Michael H.; Martin, Richard W.; Baumgartner, Scott W.; Park, Grace S.; Mancini, Edward L.; Genovese, Mark C.

In: Arthritis Care and Research, Vol. 63, No. 3, 03.2011, p. 373-382.

Research output: Contribution to journalArticle

Weinblatt, ME, Bathon, JM, Kremer, JM, Fleischmann, RM, Schiff, MH, Martin, RW, Baumgartner, SW, Park, GS, Mancini, EL & Genovese, MC 2011, 'Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis', Arthritis Care and Research, vol. 63, no. 3, pp. 373-382. https://doi.org/10.1002/acr.20372
Weinblatt, Michael E. ; Bathon, Joan M. ; Kremer, Joel M. ; Fleischmann, Roy M. ; Schiff, Michael H. ; Martin, Richard W. ; Baumgartner, Scott W. ; Park, Grace S. ; Mancini, Edward L. ; Genovese, Mark C. / Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. In: Arthritis Care and Research. 2011 ; Vol. 63, No. 3. pp. 373-382.
@article{8f8749f52e684980acd7b31d892e5047,
title = "Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis",
abstract = "Objective. To evaluate the long-term safety and efficacy of etanercept therapy in rheumatoid arthritis (RA) patients. Methods. Adult patients with early RA or longstanding RA received etanercept in open-label extension studies following initial double-blind trials of etanercept. Results. Of 558 early RA patients and 714 longstanding RA patients who received at least 1 dose of etanercept, a total of 194 early RA patients and 217 longstanding RA patients were treated with 25 mg of etanercept twice weekly through 10 years. Five opportunistic infections were reported: in early RA, 1 Candida septicemia; in longstanding RA, 1 herpes zoster, 1 atypical mycobacterium infection, 1 meningoencephalitis (unspecified), and 1 fungal sepsis (unspecified). Twenty-nine cases of sepsis occurred (10 early RA, 19 longstanding RA). Occurrence of all malignancies was similar to that expected in the general population, but the occurrence of lymphomas was higher than expected in the general population. Fourteen lymphomas (7 early RA, 7 longstanding RA) and 2 cases of demyelinating disease (1 early RA, 1 longstanding RA) were reported. Deaths occurred in 18 early RA patients and 43 longstanding RA patients. Both patient groups showed sustained improvement in American College of Rheumatology responses, swollen joint counts, Health Assessment Questionnaire disability index scores, and C-reactive protein levels. Conclusion. Etanercept maintained therapeutic benefits beyond 10 years of therapy in both early RA and longstanding RA patients, suggesting that etanercept is well tolerated and effective as a long-term, continuous therapy for the treatment of RA, with a favorable risk/benefit ratio.",
author = "Weinblatt, {Michael E.} and Bathon, {Joan M.} and Kremer, {Joel M.} and Fleischmann, {Roy M.} and Schiff, {Michael H.} and Martin, {Richard W.} and Baumgartner, {Scott W.} and Park, {Grace S.} and Mancini, {Edward L.} and Genovese, {Mark C.}",
year = "2011",
month = "3",
doi = "10.1002/acr.20372",
language = "English (US)",
volume = "63",
pages = "373--382",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

AU - Weinblatt, Michael E.

AU - Bathon, Joan M.

AU - Kremer, Joel M.

AU - Fleischmann, Roy M.

AU - Schiff, Michael H.

AU - Martin, Richard W.

AU - Baumgartner, Scott W.

AU - Park, Grace S.

AU - Mancini, Edward L.

AU - Genovese, Mark C.

PY - 2011/3

Y1 - 2011/3

N2 - Objective. To evaluate the long-term safety and efficacy of etanercept therapy in rheumatoid arthritis (RA) patients. Methods. Adult patients with early RA or longstanding RA received etanercept in open-label extension studies following initial double-blind trials of etanercept. Results. Of 558 early RA patients and 714 longstanding RA patients who received at least 1 dose of etanercept, a total of 194 early RA patients and 217 longstanding RA patients were treated with 25 mg of etanercept twice weekly through 10 years. Five opportunistic infections were reported: in early RA, 1 Candida septicemia; in longstanding RA, 1 herpes zoster, 1 atypical mycobacterium infection, 1 meningoencephalitis (unspecified), and 1 fungal sepsis (unspecified). Twenty-nine cases of sepsis occurred (10 early RA, 19 longstanding RA). Occurrence of all malignancies was similar to that expected in the general population, but the occurrence of lymphomas was higher than expected in the general population. Fourteen lymphomas (7 early RA, 7 longstanding RA) and 2 cases of demyelinating disease (1 early RA, 1 longstanding RA) were reported. Deaths occurred in 18 early RA patients and 43 longstanding RA patients. Both patient groups showed sustained improvement in American College of Rheumatology responses, swollen joint counts, Health Assessment Questionnaire disability index scores, and C-reactive protein levels. Conclusion. Etanercept maintained therapeutic benefits beyond 10 years of therapy in both early RA and longstanding RA patients, suggesting that etanercept is well tolerated and effective as a long-term, continuous therapy for the treatment of RA, with a favorable risk/benefit ratio.

AB - Objective. To evaluate the long-term safety and efficacy of etanercept therapy in rheumatoid arthritis (RA) patients. Methods. Adult patients with early RA or longstanding RA received etanercept in open-label extension studies following initial double-blind trials of etanercept. Results. Of 558 early RA patients and 714 longstanding RA patients who received at least 1 dose of etanercept, a total of 194 early RA patients and 217 longstanding RA patients were treated with 25 mg of etanercept twice weekly through 10 years. Five opportunistic infections were reported: in early RA, 1 Candida septicemia; in longstanding RA, 1 herpes zoster, 1 atypical mycobacterium infection, 1 meningoencephalitis (unspecified), and 1 fungal sepsis (unspecified). Twenty-nine cases of sepsis occurred (10 early RA, 19 longstanding RA). Occurrence of all malignancies was similar to that expected in the general population, but the occurrence of lymphomas was higher than expected in the general population. Fourteen lymphomas (7 early RA, 7 longstanding RA) and 2 cases of demyelinating disease (1 early RA, 1 longstanding RA) were reported. Deaths occurred in 18 early RA patients and 43 longstanding RA patients. Both patient groups showed sustained improvement in American College of Rheumatology responses, swollen joint counts, Health Assessment Questionnaire disability index scores, and C-reactive protein levels. Conclusion. Etanercept maintained therapeutic benefits beyond 10 years of therapy in both early RA and longstanding RA patients, suggesting that etanercept is well tolerated and effective as a long-term, continuous therapy for the treatment of RA, with a favorable risk/benefit ratio.

UR - http://www.scopus.com/inward/record.url?scp=79960141758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960141758&partnerID=8YFLogxK

U2 - 10.1002/acr.20372

DO - 10.1002/acr.20372

M3 - Article

C2 - 20957659

AN - SCOPUS:79960141758

VL - 63

SP - 373

EP - 382

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -